ArticleAngewandte Chemie (International ed. in English)2017
Systemic Delivery of Bc12-Targeting siRNA by DNA Nanoparticles Suppresses Cancer Cell Growth.
Article in Angewandte Chemie (International ed. in English), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 131 citations in OpenAlex.
- Programmable DNA Logic Systems for Applications in Biomedicine.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- DNA origami-based drug delivery and cell manipulation: toward intelligent nanomedicine.RSC chemical biology · 2026Review
- Review
- Recycling Materials for Sustainable DNA Origami Manufacturing.Nano letters · 2024Article
- DNA-based nanostructures for RNA delivery.Medical review (2021) · 2024Review
- DNA-Based Nanostructured Platforms as Drug Delivery Systems.Chem & bio engineering · 2024Review
- Structural DNA nanotechnology at the nexus of next-generation bio-applications: challenges and perspectives.Nanoscale advances · 2024Review
- Spatiotemporal Control over Polynucleotide Brush Growth on DNA Origami Nanostructures.Angewandte Chemie (International ed. in English) · 2023Article
- Application and prospects of nucleic acid nanomaterials in tumor therapy.RSC advances · 2023Review
- Size-Controlled DNA Tile Self-Assembly Nanostructures Through Caveolae-Mediated Endocytosis for Signal-Amplified Imaging of MicroRNAs in Living Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Review
- Nucleic acid nanostructures forApplied physics reviews · 2023Review
- Nucleic acid nanoassembly-enhanced RNA therapeutics and diagnosis.Acta pharmaceutica Sinica. B · 2023Review
- Uptake and stability of DNA nanostructures in cells: a cross-sectional overview of the current state of the art.Nanoscale · 2023Review
- Functionalizing DNA origami to investigate and interact with biological systems.Nature reviews. Materials · 2023Article
- Advanced applications of DNA nanostructures dominated by DNA origami in antitumor drug delivery.Frontiers in molecular biosciences · 2023Review
- Chemically modified DNA nanostructures for drug delivery.Innovation (Cambridge (Mass.)) · 2022Review
- Cucumber-Derived Nanovesicles Containing Cucurbitacin B for Non-Small Cell Lung Cancer Therapy.International journal of nanomedicine · 2022Article
- Innovative developments and emerging technologies in RNA therapeutics.RNA biology · 2022Article
- Pharmaceutical applications of framework nucleic acids.Acta pharmaceutica Sinica. B · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
Short interfering RNA (siRNA) is a promising molecular tool for cancer therapy, but its clinical success is limited by the lack of robust in vivo delivery systems. Rationally designed DNA nanoparticles (DNPs) have emerged as facile delivery vehicles because their physicochemical properties can be precisely controlled. Nonetheless, few studies have used DNPs to deliver siRNAs in vivo, and none has demonstrated therapeutic efficacy. Herein, we constructed a number of DNPs of rectangular and tubular shapes with varied dimensions using the modular DNA brick method for the systemic delivery of siRNA that targets anti-apoptotic protein Bcl2. The siRNA delivered by the DNPs inhibited cell growth both in vitro and in vivo, which suppressed tumor growth in a xenograft model that specifically correlated with Bcl2 depletion. This study suggests that DNPs are effective tools for the systemic delivery of therapeutic siRNA and have great potential for further clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.